Hjem › Brystkræft › Pennsylvania
Brystkræft kliniske forsøg i Pennsylvania
93 studier for Brystkræft søger deltagere på steder i Pennsylvania.
Byer i Pennsylvania
- Philadelphia56 studier
- Pittsburgh39 studier
- Harrisburg12 studier
- Allentown10 studier
- York8 studier
- Scranton6 studier
- Reading5 studier
- Lancaster4 studier
- Hazleton4 studier
- Chambersburg4 studier
- Erie3 studier
- New Castle3 studier
Officiel studietekst (engelsk)
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
- Abramson Cancer Center of the University of Pennsylvania, Philadelphia
- University of Pittsburgh Medical Center, Pittsburgh
- WellSpan York Cancer Center, York
RekruttererFase 1/2
Alder 12 og opefter · Alle køn · Opdateret 2. okt. 2026 · NCT04585750Distance-Based Exercise to Preserve Function and Prevent Disability
- UPMC Hillman Cancer Center at Butler Health System, Butler
- IRMC Cancer Center, Indiana
- UPMC Hillman Cancer Center - New Castle, New Castle
- og 2 flere
Rekrutterer
Alder 18 og opefter · Alle køn · Opdateret 2. okt. 2026 · NCT07059884Phase IIIb Study of Ribociclib + ET in Early Breast Cancer
- Consultants In Med Onco And Hema, Drexel Hill
- Univ of Pittsburg Med Ctr Pinnacle, Harrisburg
- Allegheny Health Network, Pittsburgh
RekruttererFase 3
Alder 18 til 100 · Alle køn · Opdateret 2. okt. 2026 · NCT05827081A Study on Adding Precisely Targeted Radiation Therapy (Stereotactic Body Radiation Therapy) to the Usual Treatment Approach (Drug Therapy) in People With Breast Cancer
- Lehigh Valley Health Network (Data Collection Only), Allentown
RekruttererFase 2
Alder 18 og opefter · Alle køn · Opdateret 2. okt. 2026 · NCT05534438Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- Lehigh Valley Hospital-Cedar Crest, Allentown
- Lehigh Valley Hospital - Muhlenberg, Bethlehem
- Geisinger Medical Center, Danville
- og 7 flere
RekruttererObservationsstudieFrivillige med god helbredstilstand velkomne
Alder 40 til 75 · Alle køn · Opdateret 2. okt. 2026 · NCT05334069A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer
- Alliance Cancer Specialists, Horsham
- University of Pennsylvania, Abramson Cancer Center, Perelman Center for Advanced Medicine, Philadelphia
- University of Pittsburgh (UPMC), Pittsburgh
RekruttererFase 2
Alder 18 og opefter · Alle køn · Opdateret 1. okt. 2026 · NCT06369285Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
- Penn State Milton S. Hershey Medical Center, Hershey
RekruttererFase 1/2
Alder 18 og opefter · Alle køn · Opdateret 30. sep. 2026 · NCT06324357Prospective Study of EXErcise Regimens After Treatment for Breast Cancer for Hypertrophy and Conditioning
- Allegheny General Hospital, Pittsburgh
RekruttererObservationsstudie
Alder 20 til 89 · Kvinder · Opdateret 30. sep. 2026 · NCT07023887A Pilot Study Assessing Myokines During an EXErcise Regimen After Treatment for Breast Cancer
- AHN Allegheny General Hospital, Pittsburgh
- Allegheny General Hospital, Pittsburgh
Rekrutterer
Alder 20 til 89 · Kvinder · Opdateret 30. sep. 2026 · NCT07698314A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation
- Research Site, Pittsburgh
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 29. sep. 2026 · NCT05877599EXERT-BC Protein: Protein Supplementation to Improve Body Composition After Treatment for Breast Cancer
- AHN Allegheny General Hospital, Pittsburgh
- AHN Allegheny General Hospital, Pittsburgh
Rekrutterer
Alder 20 til 89 · Kvinder · Opdateret 28. sep. 2026 · NCT07704476Study of AVZO-021 in Patients With Advanced Solid Tumors
- Avenzo Therapeutics Recruiting Site, Philadelphia
RekruttererFase 1/2
Alder 18 og opefter · Alle køn · Opdateret 28. sep. 2026 · NCT05867251A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)
- University of Pittsburgh Medical Center Magee-Womens Hospital ( Site 0058), Pittsburgh
- Cancer Care Associates Of York ( Site 0063), York
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 28. sep. 2026 · NCT07060807Multicenter Trial for Eliminating Breast Cancer Surgery or Radiotherapy in Exceptional Responders to Neoadjuvant Systemic Therapy
- University of Pittsburgh Cancer Institute (UPCI), Pittsburgh
Rekrutterer
Alder 30 og opefter · Kvinder · Opdateret 25. sep. 2026 · NCT02945579A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
- Thomas Jefferson University - Clinical Research Institute ( Site 0056), Philadelphia
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 25. sep. 2026 · NCT06312176The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study
- Penn Medicine - Lancaster General Hospital, Lancaster
- Capital Health Hematology Oncology Specialists, Newton
- Penn Medicine - Perelman Center for Advanced Medicine, Philadelphia
- og 2 flere
RekruttererFase 3
Alder 60 og opefter · Alle køn · Opdateret 25. sep. 2026 · NCT06377852Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer
- Clinical Trial Site, Horsham
- Clinical Trial Site, Sayre
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 23. sep. 2026 · NCT07085767Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer
- Allegheny (AHN), Pittsburgh
Rekrutterer
Alder 18 og opefter · Alle køn · Opdateret 23. sep. 2026 · NCT07214532A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
- St. Luke's University Health Network, Bethlehem
- Lancaster General Hospital - Ann B Barshinger Cancer Institute, Lancaster
- University of Pennsylvania Hospital, Philadelphia
- og 3 flere
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 22. sep. 2026 · NCT07174336A Study of LY4257496 in Participants With Cancer (OMNIRAY)
- University of Pittsburgh Medical Center, Pittsburgh
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 22. sep. 2026 · NCT07114601A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
- University of Pennsylvania, Philadelphia
- Fox Chase Cancer Center, Philadelphia
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 22. sep. 2026 · NCT07213791Evolutionary Clinical Trial for Novel Biomarker-Driven Therapies
- University of Pennsylvania/Abramson Cancer Center, Philadelphia
RekruttererFase 2
Alder 18 og opefter · Alle køn · Opdateret 18. sep. 2026 · NCT07340541Identifying Patterns in the Breath of Individuals With Breast Cancer
- Weinstein Imaging Associates, Pittsburgh
RekruttererObservationsstudieFrivillige med god helbredstilstand velkomne
Alder 40 til 74 · Kvinder · Opdateret 18. sep. 2026 · NCT06512350A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
- Lehigh Valley Health Network - Cedar Crest, Allen
- Consultants In Medical Oncology and Hematology, P.C., Broomall
- Penn State Milton S. Hershey Medical Center, Hershey
- og 5 flere
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 15. sep. 2026 · NCT06492616A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
- Research Site, Pittsburgh
RekruttererFase 1/2
Alder 18 og opefter · Alle køn · Opdateret 11. sep. 2026 · NCT05123482Active Surveillance in Older Women With ER+ Breast Cancer
- University of Pittsburgh Medical Center, Pittsburgh
RekruttererObservationsstudie
Alder 70 og opefter · Kvinder · Opdateret 11. sep. 2026 · NCT07262138A Trial to Evaluate Ovarian Suppression Following Subcutaneous ZOLADEX 10.8 mg in Premenopausal Women With Early-stage and Advanced HR+ Breast Cancer
- St. Luke's University Health Network, Bethlehem
- Guthrie Medical Group, Sayre
RekruttererFase 1
Alder 18 til 55 · Kvinder · Opdateret 9. sep. 2026 · NCT07310420A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer
- Penn State Health Milton S. Hershey Medical Center, Hershey
- University of Pennsylvania - Abramson Cancer Center, Philadelphia
- UPMC - Hillman Cancer Center, Pittsburgh
RekruttererFase 1/2
Alder 18 og opefter · Alle køn · Opdateret 8. sep. 2026 · NCT07100106Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration
- University of Pennsylvania, Philadelphia
RekruttererFase 1/2
Alder 18 og opefter · Alle køn · Opdateret 4. sep. 2026 · NCT05315700Trial of Pre-operative Neratinib and Endocrine Therapy With Trastuzumab in ER-Positive, HER-2 Positive Breast Cancers
- Penn State Cancer Institute, Hershey
RekruttererFase 2
Alder 18 og opefter · Alle køn · Opdateret 3. sep. 2026 · NCT04886531A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
- UPMC Hillman Cancer Center - Magee-Women?s Hospital, Pittsburgh
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 3. sep. 2026 · NCT06790693FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors
- Thomas Jefferson University, Sidney Kimmel Cancer Center, Philadelphia
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 2. sep. 2026 · NCT07216105Improving Survival for Metastatic Lobular Breast Cancer (PLUMB Registry)
- Abramson Cancer Center, Philadelphia
RekruttererObservationsstudie
Alder 18 og opefter · Alle køn · Opdateret 2. sep. 2026 · NCT05964504Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
- Lehigh Valley Hospital-Cedar Crest, Allentown
- Lehigh Valley Hospital - Muhlenberg, Bethlehem
- Bryn Mawr Hospital, Bryn Mawr
- og 56 flere
RekruttererFase 3
Alder 18 til 60 · Kvinder · Opdateret 2. sep. 2026 · NCT05879926A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors
- UPMC Hillman Cancer Center, Pittsburgh
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 28. aug. 2026 · NCT07029399A Phase 1 Study of LNCB74 in Advanced Solid Tumors
- Sidney Kimmel Comprehensive Center at Jefferson, Philadelphia
- UPMC, Pittsburgh
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 21. aug. 2026 · NCT06774963Biennial CEM in Women With a Personal History of Breast Cancer
- UPMC Magee-Womens Imaging - Bethel Park, Bethel Park
- UPMC Magee at the Lemieux Sports Complex, Cranberry Township
- Magee Womancare Monroeville, Monroeville
- og 3 flere
RekruttererFrivillige med god helbredstilstand velkomne
Alder 30 til 79 · Kvinder · Opdateret 19. aug. 2026 · NCT06105749ATEMPT 2.0: Adjuvant T-DM1 vs TH
- University of Pennsylvania, Abramson Cancer Center, Philadelphia
- University of Pittsburgh Medical Center Cancer UPMC- Magee Women's Hospital, Pittsburgh
RekruttererFase 2
Alder 18 og opefter · Alle køn · Opdateret 19. aug. 2026 · NCT04893109PENN-Surveillance Markers of Utility for Recurrence After (Neo)Adjuvant Therapy for Breast Cancer
- Abramson Cancer Center of the University of Pennsylvania, Philadelphia
Rekrutterer
Alder 18 og opefter · Alle køn · Opdateret 19. aug. 2026 · NCT02732171EXERT-BC Cardio: Cardio or Conditioning Training With Breast Cancer
- AHN Allegheny General Hospital, Pittsburgh
Rekrutterer
Alder 20 til 89 · Kvinder · Opdateret 17. aug. 2026 · NCT07739563Fra ClinicalTrials.gov, data hentet 5. okt. 2026. Hver studie har sine egne kvalifikationskrav; studieteamet afgør, hvem der kan deltage.